Literature DB >> 3529570

Detection of transitional cell carcinoma in bladder by intravesical injection of monoclonal antibodies.

D K Chopin, J B deKernion.   

Abstract

Monoclonal antibodies produced against tumor associated antigens of human bladder transitional cell carcinoma have proved to be useful in detecting malignant cells in tumor sections and bladder washings. The present study evaluated the capacity of one such antibody G4 to identify sites of malignancy when introduced into the lumen of intact bladders immediately after cystectomy. An ex vivo immunoperoxidase staining (IPS) method was applied to four cystectomy specimens--three with solitary invasive transitional cell carcinomas (TCC) and one with carcinoma in situ (CIS) using monoclonal antibody G4 injected intravesically immediately after cystectomy. The tumor sites, normal appearing mucosa and other exposed and non exposed tissues from the same patient were examined for G4 binding. In all cases preferential intravesical binding of G4 antibody to the tumor size was demonstrated without binding to the normal mucosa except in one case. This study showed that monoclonal antibody injected intravesically can be focused on the tumor site and indicates that G4 and other antibodies may be useful intravesically for selectively assessing field changes associated with malignancies or as specific therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529570     DOI: 10.1007/bf00255834

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  14 in total

1.  Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy.

Authors:  M M MELICOW
Journal:  J Urol       Date:  1952-07       Impact factor: 7.450

2.  The association of urothelial atypism with neoplasia: its importance in treatment and prognosis.

Authors:  R O Schade; J Swinney
Journal:  J Urol       Date:  1973-04       Impact factor: 7.450

3.  In vivo urothelial surface histology by microscopic chromocystoscopy.

Authors:  W B Gill; J L Huffman; E S Lyon; D H Bagley
Journal:  J Urol       Date:  1983-10       Impact factor: 7.450

4.  Serial multiple-site biopsies in patients with bladder cancer.

Authors:  M S Soloway; W Murphy; M K Rao; C Cox
Journal:  J Urol       Date:  1978-07       Impact factor: 7.450

5.  Bladder cancer as seen in giant histologic sections.

Authors:  E A Soto; G H Friedell; A J Tiltman
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

6.  The association of urothelial abnormalities with neoplasia: a 10-year followup.

Authors:  R O Schade; J Swinney
Journal:  J Urol       Date:  1983-06       Impact factor: 7.450

7.  Analysis of 90 step-sectioned cystectomized specimens of bladder cancer.

Authors:  T Kakizoe; K Matsumoto; Y Nishio; K Kishi
Journal:  J Urol       Date:  1984-03       Impact factor: 7.450

8.  In vivo staining test with methylene blue for bladder cancer.

Authors:  I Fukui; M Yokokawa; G Mitani; F Ohwada; M Wakui; M Washizuka; T Tohma; K Igarashi; T Yamada
Journal:  J Urol       Date:  1983-08       Impact factor: 7.450

9.  Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future new occurrences.

Authors:  H Wolf; K Højgaard
Journal:  Lancet       Date:  1983-07-16       Impact factor: 79.321

10.  Murine hybridoma antibodies against human transitional carcinoma-associated antigens.

Authors:  E M Messing; J E Bubbers; K E Whitmore; J B deKernion; M S Nestor; J L Fahey
Journal:  J Urol       Date:  1984-07       Impact factor: 7.450

View more
  2 in total

1.  Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors.

Authors:  C Cordon-Cardo; D D Wartinger; M R Melamed; W Fair; Y Fradet
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

2.  Specific targeting and toxicity of sulphonated aluminium phthalocyanine photosensitised liposomes directed to cells by monoclonal antibody in vitro.

Authors:  J Morgan; A G Gray; E R Huehns
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.